"Anilides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any aromatic amide obtained by acylation of aniline.
Descriptor ID |
D000813
|
MeSH Number(s) |
D02.065.199 D02.092.146.113
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anilides".
Below are MeSH descriptors whose meaning is more specific than "Anilides".
This graph shows the total number of publications written about "Anilides" by people in this website by year, and whether "Anilides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2004 | 1 | 1 | 2 |
2005 | 0 | 3 | 3 |
2006 | 1 | 1 | 2 |
2007 | 1 | 1 | 2 |
2008 | 0 | 2 | 2 |
2009 | 0 | 1 | 1 |
2010 | 3 | 3 | 6 |
2011 | 3 | 2 | 5 |
2012 | 5 | 1 | 6 |
2013 | 4 | 5 | 9 |
2014 | 6 | 4 | 10 |
2015 | 9 | 3 | 12 |
2016 | 5 | 5 | 10 |
2017 | 7 | 3 | 10 |
2018 | 8 | 1 | 9 |
2019 | 3 | 2 | 5 |
2020 | 6 | 1 | 7 |
2021 | 5 | 5 | 10 |
2022 | 1 | 7 | 8 |
2023 | 0 | 2 | 2 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anilides" by people in Profiles.
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Apr; 9(4):310-322.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 12 15; 83(24):4161-4178.
-
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023 07; 18(7):907-921.
-
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022 12 15; 128(24):4203-4212.
-
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na?ve RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep; 18(28):3143-3150.
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 08; 23(8):995-1008.
-
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022 10; 40(5):990-1000.
-
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 07; 23(7):888-898.